Biohaven Ltd. Other Comprehensive Income (Loss), Net of Tax
Biohaven Ltd. (BHVN) reported Other Comprehensive Income (Loss), Net of Tax of -$2.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-10
- Biohaven Ltd. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$2.93M.
- Biohaven Ltd. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$46.00K.
- Biohaven Ltd. other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was $8.31M.
- Biohaven Ltd. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $39.00K, a 82.11% decline year-over-year.
- Biohaven Ltd. other comprehensive income (loss), net of tax for fiscal 2025 was $8.27M, a 5642.36% increase from fiscal 2024.
- Biohaven Ltd. other comprehensive income (loss), net of tax for fiscal 2024 was $144.00K.
- Biohaven Ltd. other comprehensive income (loss), net of tax for fiscal 2023 was -$349.00K, a 222.89% decline from fiscal 2022.
- Biohaven Ltd. other comprehensive income (loss), net of tax for fiscal 2022 was $284.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.93M 10-Q · filed 2026-08-10 | -$2.97M 10-Q · filed 2026-08-10 | $5.34M derived: sum of 3 quarters · filed 2026-08-10 | $5.38M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$46.00K 10-Q · filed 2026-05-04 | $8.27M derived: sum of 2 quarters · filed 2026-05-04 | $8.30M derived: sum of 3 quarters · filed 2026-05-04 | $8.23M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $8.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $8.35M derived: sum of 2 quarters · filed 2026-03-02 | $8.28M derived: sum of 3 quarters · filed 2026-08-10 | $8.27M 10-K · filed 2026-03-02 |
| 2025-09-30 | $39.00K 10-Q · filed 2025-11-10 | -$37.00K derived: sum of 2 quarters · filed 2026-08-10 | -$43.00K 10-Q · filed 2025-11-10 | -$104.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$76.00K 10-Q · filed 2026-08-10 | -$82.00K 10-Q · filed 2026-08-10 | -$143.00K derived: sum of 3 quarters · filed 2026-08-10 | $75.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$6.00K 10-Q · filed 2026-05-04 | -$67.00K derived: sum of 2 quarters · filed 2026-05-04 | $151.00K derived: sum of 3 quarters · filed 2026-05-04 | $179.00K derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $157.00K derived: sum of 2 quarters · filed 2026-03-02 | $185.00K derived: sum of 3 quarters · filed 2026-03-02 | $144.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $218.00K 10-Q · filed 2025-11-10 | $246.00K derived: sum of 2 quarters · filed 2025-11-10 | $205.00K 10-Q · filed 2025-11-10 | -$18.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $28.00K 10-Q · filed 2025-08-11 | -$13.00K 10-Q · filed 2025-08-11 | -$236.00K derived: sum of 3 quarters · filed 2026-03-02 | -$98.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$41.00K 10-Q · filed 2025-05-12 | -$264.00K derived: sum of 2 quarters · filed 2026-03-02 | -$126.00K derived: sum of 3 quarters · filed 2026-03-02 | -$272.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$223.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$85.00K derived: sum of 2 quarters · filed 2026-03-02 | -$231.00K derived: sum of 3 quarters · filed 2026-03-02 | -$349.00K 10-K · filed 2026-03-02 |
| 2023-09-30 | $138.00K 10-Q · filed 2024-11-12 | -$8.00K derived: sum of 2 quarters · filed 2024-11-12 | -$126.00K 10-Q · filed 2024-11-12 | $158.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$146.00K 10-Q · filed 2024-08-09 | -$264.00K 10-Q · filed 2024-08-09 | $20.00K derived: sum of 3 quarters · filed 2025-03-03 | $20.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$118.00K 10-Q · filed 2024-05-09 | $166.00K derived: sum of 2 quarters · filed 2025-03-03 | $166.00K derived: sum of 3 quarters · filed 2025-03-03 | $166.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $284.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $284.00K derived: sum of 2 quarters · filed 2025-03-03 | $284.00K derived: sum of 3 quarters · filed 2025-03-03 | $284.00K 10-K · filed 2025-03-03 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-07-31 | $0.00 10-Q · filed 2023-07-31 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |